Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Milestone Scientific (MLSS) has announced the promotion of Jan Adriaan Haverhals to President, effective immediately. Haverhals, who joined the company in June 2020 as President and CEO of Wand Dental, brings over 30 years of experience in sales and marketing within the medical device sector. His leadership is expected to accelerate the commercialization of Milestone's CompuFlo® Epidural Instrument and CathCheck™ technologies in the U.S. and Europe. Leonard Osser, Interim CEO, expressed confidence in Haverhals' abilities to enhance sales and marketing efforts and foster collaborations with major health systems.
Milestone Scientific (NYSE American: MLSS) announced its participation in the LD 500 virtual investor conference from September 1-4, 2020. Interim CEO Len Osser will present on September 1 at 2:40 p.m. ET. The presentation will be available via a live webcast on the conference platform. One-on-one meetings can be requested online or via email. The LD 500 event will showcase key players in the small and micro-cap sector, featuring interviews and keynote speeches. For more details on Milestone Scientific's technology and services, visit their website.
Milestone Scientific (NYSE:MLSS) reported Q2 2020 revenues of approximately $167,000, down from $2.2 million in Q2 2019, significantly impacted by the COVID-19 pandemic. The operating loss for the quarter increased to approximately $(3.1) million, compared to $(1.1) million in the prior year. For the first six months, revenues dropped to $1.9 million from $4.1 million in H1 2019. Despite the downturn, the company ended the quarter with over $16.6 million in cash, allowing it to enhance sales activities and adapt to market conditions. The focus remains on the commercialization of the CompuFlo Epidural System.
Milestone Scientific Inc. (MLSS) announced a conference call on August 17, 2020, at 8:30 AM ET, to discuss its financial results for Q2 2020 ending June 30. The call aims to cover corporate progress and developments. Investors can participate via the company's website or by telephone. A replay will be available within an hour after the call until August 31, 2020. Milestone Scientific focuses on innovative drug delivery instruments that enhance injection precision and comfort, utilizing its proprietary Dynamic Pressure Sensing technology.
Milestone Scientific (NYSE American: MLSS) has announced a conference call scheduled for August 17, 2020, at 8:30 AM ET to discuss its financial results for Q2 2020 and corporate developments. Interested parties can access the call via the company's website or by dialing the appropriate toll-free numbers. The call will also be archived for later access. Milestone specializes in innovative injection technologies aimed at providing painless and precise injections, utilizing their proprietary DPS Dynamic Pressure Sensing technology.